Hao Xu’s Post

We are almost at the end of March, have you submitted your PHUSE EU Connect 2024 abstract to the Call for Papers system yet? We have lots of streams for you to submit to, see below for further information! #PHUSE #EUConnect #DataVisualisation

Who can submit an abstract in the Professional Development stream? ANYONE! Senior leader ✅ Manager ✅ Newbie ✅ In IT ✅ In stats ✅ In data science ✅ All you need to have is a great idea and topic to help people to develop professionally! 💡Read a great book that helped with your time management? 💡Learned a model that helped with accountability? 💡Want to talk about something relevant to today’s working environment? Get your abstracts in! Diana Stuart Dave Barrett and I can’t wait to see them! And as always, if you’re not sure, drop one of us a message! #phuseeu #professionaldevelopment

I've learned more in life after a loss than from a win. Here's 8 real-world case studies that reveal the challenges and invaluable lessons learned from drug development programs and clinical trials failing to achieve regulatory approval. https://lnkd.in/e_ahz9tZ #Resilience #GrowthMindset #Leadership #drugdevelopment #drugdiscovery #clinicaltrials #pharmaceutical #biotech #lifesciences

Loved working on this to bring so many pharma and medtech launch issues into focus. With approximately 90% of candidates entering clinical trials failing to achieve regulatory approval, understanding the reasons behind these failures is crucial for companies aiming to future-proof their product candidates. Read our latest whitepaper, “Learning the Lessons of Failure: How to improve the economics of Life Sciences R&D” and dive deep into eight real-world case studies that reveal the challenges and invaluable lessons learned from drug development programs. View here: ow.ly/BLgz30sBPYl #clinicaltrial #drugdevelopment #regulatory #pharma #medtech

'Design and Conduct of Bioequivalence Studies' workshop is coming up. The main objective of this 3-day workshop is to provide an up-to-date overview of bioequivalence testing, focusing on the scientific, industrial as well as regulatory perspectives. It will cover planning, conduct, analysis and reporting bioequivalence studies according to current regulatory requirements. The course will also touch on the physicochemical and formulation factors that affect drug bioavailability and bioequivalence during the drug development process. The following topics will be covered: - Study Protocol (Planning and Conduct of BE Studies) - Clinical Study Procedures - Analytical Study Procedures - Evaluation of BE Studies and Reporting Registration link: https://lnkd.in/dkkMHQtP

📣 We’ve just released the 2024 Regulatory Readiness & Resources Report based on input from nearly 700 respondents! Sponsored content from Celegence: The survey was sent industry-wide, conducted by RAPS and co-sponsored with Celegence, a RAPS partner. The eye-opening results from this benchmark survey informs future trends and investments for the Life Sciences industry. The results are broken out into two different reports to showcase results from both the Pharmaceutical and Medical Device industries Key findings reveal: ✅ Industry is increasing focus on managing resources, with bandwidth/resources the #1 challenge ✅ 77% in Medical Devices, 55% in Pharma have insufficient resources for all of 2024 priorities ✅ AI early adoption use cases include data extraction, report generation and medical writing 👉 Download your copy today: https://bit.ly/4ehay8v A huge thank you to those who participated and contributed to the survey! #regulatory #regulatoryaffairs #regulatorycompliance

📢Sharing an Insightful Report on our LinkedIn - 2024 Regulatory Readiness & Resources📢 Sponsored content from Celegence: Together with Regulatory Affairs Professionals Society (RAPS), Celegence, a renowned RAPS partner, conducted a comprehensive survey gathering valuable insights from almost 700 respondents across the Life Sciences industry. The findings of this benchmark study will help shape future trends and investments. 📑The survey results are presented in two reports showcasing the Pharmaceutical and Medical Device sectors. 🔑Key Takeaways: 💼 #LifeSciences industry is ramping up efforts in resource management, with bandwidth/resources as the top challenge. 🚨 77% in the #MedicalDevices sector and 55% in Pharma report insufficient resources for their 2024 priorities. 🤖 AI early adoption use cases involve data extraction, report generation, and medical writing. Don't miss out on valuable insights that can impact the future of the Life Sciences industry! https://bit.ly/4ewPQl2

With approximately 90% of candidates entering clinical trials failing to achieve regulatory approval, understanding the reasons behind these failures is crucial for companies aiming to future-proof their product candidates. Read our latest whitepaper, “Learning the Lessons of Failure: How to improve the economics of Life Sciences R&D” and dive deep into eight real-world case studies that reveal the challenges and invaluable lessons learned from drug development programs. View here: https://lnkd.in/gRdwyVcX #clinicaltrial #drugdevelopment #regulatory

[Expert interview] 🤝 Meet our technical expert in #solidstate characterization and scalable #crystallization process, Dr. Julien LEROUDIER.  Julien holds a PhD from university of Grenoble, on crystal growth and works at SEQENS as the Solid State department manager of the Seqen’s Lab, in Porcheville. 𝐖𝐞 𝐚𝐬𝐤𝐞𝐝 𝐡𝐢𝐦 𝟗 𝐪𝐮𝐞𝐬𝐭𝐢𝐨𝐧𝐬: ✔️ What is your background? ✔️ How do you correlate poor bioavailability with solid form properties of a Drug candidate? ✔️ How can you improve bioavailability through solid state activities? ✔️ What does it mean to assess developability at early-stage Discovery? ✔️ How do you evaluate the solid form properties? ✔️What is the most common solid form of drug substances approved by FDA? ✔️ What kind of issues related to drug development do you usually encounter? ✔️How can you accelerate the screening forms activities? ✔️The benefits of solid forms selection at early clinical stage – What’s next?   👉 Discover his answers below and read the full article in our knowledge center ➡️ https://lnkd.in/eSQ2JgYM   If you missed Julien's 𝐰𝐞𝐛𝐢𝐧𝐚𝐫 about / 𝐇𝐨𝐰 𝐭𝐨 𝐜𝐨𝐧𝐭𝐫𝐨𝐥 𝐭𝐡𝐞 𝐬𝐨𝐥𝐢𝐝 𝐟𝐨𝐫𝐦 𝐨𝐟 𝐲𝐨𝐮𝐫 𝐀𝐏𝐈 𝐟𝐨𝐫 𝐡𝐢𝐠𝐡𝐞𝐫 𝐛𝐢𝐨𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐚𝐧𝐝 𝐞𝐚𝐬𝐢𝐞𝐫 𝐝𝐫𝐮𝐠 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 / ➡️ contact us by email to access the full recording: [email protected]   Within our 𝐒𝐞𝐪𝐞𝐧𝐬𝐔𝐏! 𝐎𝐟𝐟𝐞𝐫, our dedicated team offers solutions for solving bioavailability issues of APIs. Contact 𝐜𝐫𝐨@𝐬𝐞𝐪𝐞𝐧𝐬.𝐜𝐨𝐦 to know more! #Seqens #Seqenspharmaceuticals #ourscienceforyourfuture #Science #PharmaceuticalScience #DrugDiscovery #SolidStateChemistry #Bioavailability #DrugDevelopment #ExpertInterview #Crystallization #API #SolidFormSelection #Webinars